Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.
Identifieur interne : 000398 ( PubMed/Curation ); précédent : 000397; suivant : 000399Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.
Auteurs : Sara Bellefqih [Maroc] ; Sanaa Elmajjaoui [Maroc] ; Jihan Aarab [Maroc] ; Jihane Khalil [Maroc] ; Mohamed Afif [Maroc] ; Amine Lachgar [Maroc] ; Hanan El Kacemi [Maroc] ; Tayeb Kebdani [Maroc] ; Noureddine Benjaafar [Maroc]Source :
- International journal of radiation oncology, biology, physics [ 1879-355X ] ; 2017.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antinéoplasiques (usage thérapeutique), Antinéoplasiques hormonaux (usage thérapeutique), Facteurs temps, Femelle, Humains, Hyperpigmentation (étiologie), Hypofractionnement de dose, Irradiation ganglionnaire (), Irradiation ganglionnaire (effets indésirables), Mastectomie partielle, Métastase lymphatique, Pronostic, Récepteur ErbB-2 (antagonistes et inhibiteurs), Récidive tumorale locale, Région mammaire, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Thorax, Tumeurs du sein (), Tumeurs du sein (anatomopathologie), Tumeurs du sein (radiothérapie), Télangiectasie (étiologie), Études de suivi, Études rétrospectives.
- MESH :
- anatomopathologie : Tumeurs du sein.
- antagonistes et inhibiteurs : Récepteur ErbB-2.
- effets indésirables : Irradiation ganglionnaire.
- radiothérapie : Tumeurs du sein.
- usage thérapeutique : Antinéoplasiques, Antinéoplasiques hormonaux.
- étiologie : Hyperpigmentation, Télangiectasie.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Hypofractionnement de dose, Irradiation ganglionnaire, Mastectomie partielle, Métastase lymphatique, Pronostic, Récidive tumorale locale, Région mammaire, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Thorax, Tumeurs du sein, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents (therapeutic use), Antineoplastic Agents, Hormonal (therapeutic use), Breast, Breast Neoplasms (pathology), Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Disease-Free Survival, Dose Hypofractionation, Female, Follow-Up Studies, Humans, Hyperpigmentation (etiology), Lymphatic Irradiation (adverse effects), Lymphatic Irradiation (methods), Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Receptor, ErbB-2 (antagonists & inhibitors), Retrospective Studies, Telangiectasis (etiology), Thorax, Time Factors.
- MESH :
- chemical , antagonists & inhibitors : Receptor, ErbB-2.
- chemical , therapeutic use : Antineoplastic Agents, Antineoplastic Agents, Hormonal.
- adverse effects : Lymphatic Irradiation.
- etiology : Hyperpigmentation, Telangiectasis.
- methods : Lymphatic Irradiation.
- pathology : Breast Neoplasms.
- radiotherapy : Breast Neoplasms.
- surgery : Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Breast, Disease-Free Survival, Dose Hypofractionation, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Thorax, Time Factors.
Abstract
To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement.
DOI: 10.1016/j.ijrobp.2016.11.010
PubMed: 28126305
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000398
Links to Exploration step
pubmed:28126305Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.</title><author><name sortKey="Bellefqih, Sara" sort="Bellefqih, Sara" uniqKey="Bellefqih S" first="Sara" last="Bellefqih">Sara Bellefqih</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco. Electronic address: sara.bellefqih@gmail.com.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Elmajjaoui, Sanaa" sort="Elmajjaoui, Sanaa" uniqKey="Elmajjaoui S" first="Sanaa" last="Elmajjaoui">Sanaa Elmajjaoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Aarab, Jihan" sort="Aarab, Jihan" uniqKey="Aarab J" first="Jihan" last="Aarab">Jihan Aarab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Khalil, Jihane" sort="Khalil, Jihane" uniqKey="Khalil J" first="Jihane" last="Khalil">Jihane Khalil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Afif, Mohamed" sort="Afif, Mohamed" uniqKey="Afif M" first="Mohamed" last="Afif">Mohamed Afif</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Lachgar, Amine" sort="Lachgar, Amine" uniqKey="Lachgar A" first="Amine" last="Lachgar">Amine Lachgar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="El Kacemi, Hanan" sort="El Kacemi, Hanan" uniqKey="El Kacemi H" first="Hanan" last="El Kacemi">Hanan El Kacemi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Kebdani, Tayeb" sort="Kebdani, Tayeb" uniqKey="Kebdani T" first="Tayeb" last="Kebdani">Tayeb Kebdani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Benjaafar, Noureddine" sort="Benjaafar, Noureddine" uniqKey="Benjaafar N" first="Noureddine" last="Benjaafar">Noureddine Benjaafar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28126305</idno><idno type="pmid">28126305</idno><idno type="doi">10.1016/j.ijrobp.2016.11.010</idno><idno type="wicri:Area/PubMed/Corpus">000398</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000398</idno><idno type="wicri:Area/PubMed/Curation">000398</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000398</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.</title><author><name sortKey="Bellefqih, Sara" sort="Bellefqih, Sara" uniqKey="Bellefqih S" first="Sara" last="Bellefqih">Sara Bellefqih</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco. Electronic address: sara.bellefqih@gmail.com.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Elmajjaoui, Sanaa" sort="Elmajjaoui, Sanaa" uniqKey="Elmajjaoui S" first="Sanaa" last="Elmajjaoui">Sanaa Elmajjaoui</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Aarab, Jihan" sort="Aarab, Jihan" uniqKey="Aarab J" first="Jihan" last="Aarab">Jihan Aarab</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Khalil, Jihane" sort="Khalil, Jihane" uniqKey="Khalil J" first="Jihane" last="Khalil">Jihane Khalil</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Afif, Mohamed" sort="Afif, Mohamed" uniqKey="Afif M" first="Mohamed" last="Afif">Mohamed Afif</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Lachgar, Amine" sort="Lachgar, Amine" uniqKey="Lachgar A" first="Amine" last="Lachgar">Amine Lachgar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="El Kacemi, Hanan" sort="El Kacemi, Hanan" uniqKey="El Kacemi H" first="Hanan" last="El Kacemi">Hanan El Kacemi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Kebdani, Tayeb" sort="Kebdani, Tayeb" uniqKey="Kebdani T" first="Tayeb" last="Kebdani">Tayeb Kebdani</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author><author><name sortKey="Benjaafar, Noureddine" sort="Benjaafar, Noureddine" uniqKey="Benjaafar N" first="Noureddine" last="Benjaafar">Noureddine Benjaafar</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat</wicri:regionArea></affiliation></author></analytic><series><title level="j">International journal of radiation oncology, biology, physics</title><idno type="eISSN">1879-355X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Agents (therapeutic use)</term><term>Antineoplastic Agents, Hormonal (therapeutic use)</term><term>Breast</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (radiotherapy)</term><term>Breast Neoplasms (surgery)</term><term>Disease-Free Survival</term><term>Dose Hypofractionation</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Hyperpigmentation (etiology)</term><term>Lymphatic Irradiation (adverse effects)</term><term>Lymphatic Irradiation (methods)</term><term>Lymphatic Metastasis</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local</term><term>Prognosis</term><term>Receptor, ErbB-2 (antagonists & inhibitors)</term><term>Retrospective Studies</term><term>Telangiectasis (etiology)</term><term>Thorax</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Antinéoplasiques hormonaux (usage thérapeutique)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hyperpigmentation (étiologie)</term><term>Hypofractionnement de dose</term><term>Irradiation ganglionnaire ()</term><term>Irradiation ganglionnaire (effets indésirables)</term><term>Mastectomie partielle</term><term>Métastase lymphatique</term><term>Pronostic</term><term>Récepteur ErbB-2 (antagonistes et inhibiteurs)</term><term>Récidive tumorale locale</term><term>Région mammaire</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Thorax</term><term>Tumeurs du sein ()</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (radiothérapie)</term><term>Télangiectasie (étiologie)</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, ErbB-2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Antineoplastic Agents, Hormonal</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymphatic Irradiation</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur ErbB-2</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Irradiation ganglionnaire</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hyperpigmentation</term><term>Telangiectasis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymphatic Irradiation</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Antinéoplasiques hormonaux</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hyperpigmentation</term><term>Télangiectasie</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Breast</term><term>Disease-Free Survival</term><term>Dose Hypofractionation</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Mastectomy, Segmental</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local</term><term>Prognosis</term><term>Retrospective Studies</term><term>Thorax</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Hypofractionnement de dose</term><term>Irradiation ganglionnaire</term><term>Mastectomie partielle</term><term>Métastase lymphatique</term><term>Pronostic</term><term>Récidive tumorale locale</term><term>Région mammaire</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Thorax</term><term>Tumeurs du sein</term><term>Études de suivi</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28126305</PMID><DateCreated><Year>2017</Year><Month>01</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-355X</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of radiation oncology, biology, physics</Title><ISOAbbreviation>Int. J. Radiat. Oncol. Biol. Phys.</ISOAbbreviation></Journal><ArticleTitle>Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.</ArticleTitle><Pagination><MedlinePgn>563-570</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0360-3016(16)33432-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijrobp.2016.11.010</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To evaluate the effect of hypofractionated radiation therapy (HFRT) of the breast/chest wall and regional nodes on overall survival (OS), disease-free survival (DFS), locoregional control and on treatment-related toxicity in patients with breast cancer and nodal involvement.</AbstractText><AbstractText Label="METHODS AND MATERIALS" NlmCategory="METHODS">Two hundred fifty-seven patients treated between October 2009 and June 2011 with hypofractionated locoregional radiation therapy (42 Gy in 15 fractions) were retrospectively reviewed, 51 (19.8%) after breast-conserving surgery and 206 (80.2%) after radical surgery. Patients treated with breast-conserving surgery received a boost dose to the tumor bed (delivered by photons, electrons, or interstitial high-dose-rate brachytherapy). Two hundred fifty-six (99.6%) patients underwent chemotherapy, 209 (81.3%) had hormonal treatment, and 65 (25.3%) had anti-HER2 targeted therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median follow-up time was 64 months (range, 11-88 months). The rates of 5-year OS, DFS, locoregional recurrence (LRR)-free survival, and distant metastasis (DM)-free survival were 86.6%, 84.4%, 93.9%, and 83.1%, respectively. In multivariate analysis (MVA), lymph node ratio >65%, lymphovascular invasion, and negative hormone receptor status predicted for OS, DSF, and DM. T3 to 4 stage was also associated with worse DFS and DM. Finally, for LRR the independent prognostic factors on MVA were N2 to 3 stage and grade 3. Hyperpigmentation was observed in 19.2% of patients, telangiectasia in 12.3%, and fibrosis in 30.7%. Grade ≥2 lymphedema was recorded in 5.8% of cases. During the study follow-up, no cardiac or symptomatic pneumonitis was observed, nor were plexopathy or rib fractures.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">According to the findings from this retrospective study, HFRT seems to be an acceptable alternative for patients with breast cancer who need regional nodal irradiation. However, prospective randomized trials are necessary to confirm these preliminary results.</AbstractText><CopyrightInformation>Copyright © 2016 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellefqih</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco. Electronic address: sara.bellefqih@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmajjaoui</LastName><ForeName>Sanaa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aarab</LastName><ForeName>Jihan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalil</LastName><ForeName>Jihane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afif</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lachgar</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Kacemi</LastName><ForeName>Hanan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kebdani</LastName><ForeName>Tayeb</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjaafar</LastName><ForeName>Noureddine</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Radiotherapy, National Institute of Oncology, Mohammed V University, Rabat, Morocco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Radiat Oncol Biol Phys</MedlineTA><NlmUniqueID>7603616</NlmUniqueID><ISSNLinking>0360-3016</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069473" MajorTopicYN="N">Dose Hypofractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017495" MajorTopicYN="N">Hyperpigmentation</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015182" MajorTopicYN="N">Lymphatic Irradiation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013684" MajorTopicYN="N">Telangiectasis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013909" MajorTopicYN="N">Thorax</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>10</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>11</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28126305</ArticleId><ArticleId IdType="pii">S0360-3016(16)33432-0</ArticleId><ArticleId IdType="doi">10.1016/j.ijrobp.2016.11.010</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000398 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000398 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28126305
|texte= Hypofractionated Regional Nodal Irradiation for Women With Node-Positive Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28126305" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |